生物标志物用于脓毒症相关急性肾损伤分期的效用
本研究基于ProCESS试验数据(999例脓毒症休克患者,2008年3月至2013年5月入组),按ADQI-23框架以尿[TIMP-2]×[IGFBP7]>2.0 (ng/mL)²/1000为生物标志物阳性,检验其能否在同一功能学AKI分期内部进一步区分生存。结果显示,生物标志物阳性者在AKI 1期(RR 2.20;95%CI 1.02-4.72)、2期(RR 1.53;95%CI 1.04-2.27)和3期(RR 1.61;95%CI 1.00-2.60)30天死亡率更高;无AKI功能标准者两组30天生存无差异(RR 1.16;95%CI 0.45-3.01)。作者认为,细胞周期停滞标志物TIMP-2与IGFBP7可能增强已有功能学AKI标准患者的分期。
要点
- 在脓毒症休克且符合AKI功能学标准者中,6小时尿[TIMP-2]×[IGFBP7]>2.0 (ng/mL)²/1000与30天死亡率升高相关。
- AKI 1期生物标志物阳性者30天死亡RR 2.20(95%CI 1.02-4.72),2期RR 1.53(95%CI 1.04-2.27),3期RR 1.61(95%CI 1.00-2.60)。
- 无AKI功能学标准者,生物标志物阳性与阴性30天生存无差异(RR 1.16;95%CI 0.45-3.01)。
- 作者认为,评估细胞周期停滞标志物TIMP-2与IGFBP7可能增强已有功能学AKI标准患者的分期。
适用人群与场景
- 美国学术与社区急诊科及ICU收治的脓毒症休克危重患者,数据来自ProCESS试验,入组时间2008年3月至2013年5月。
- 排除终末期肾病、参考血清肌酐≥4 mg/dL(换算μmol/L需乘以76.25)、血清肌酐或尿[TIMP-2]×[IGFBP7]数据缺失者。
诊断标准与关键阈值
- AKI诊断依据肾脏病改善全球结局(KDIGO)标准,于入组后24小时内评估。
- 入组后6小时测定尿[TIMP-2]×[IGFBP7]水平,以既往报道的高特异性切点2.0 (ng/mL)²/1000分类:≤2.0 (ng/mL)²/1000为生物标志物阴性,>2.0 (ng/mL)²/1000为生物标志物阳性,并按ADQI-23新分期系统分类(包括无AKI功能学标准者)。
研究设计与关键结果
- 本研究为队列研究,使用ProCESS试验数据,纳入999例脓毒症休克患者,中位年龄61岁(IQR 50-73岁),男性554例(55.5%)。
- 生物标志物阳性者30天生存更低、死亡率更高:AKI 1期RR 2.20(95%CI 1.02-4.72),AKI 2期RR 1.53(95%CI 1.04-2.27),AKI 3期RR 1.61(95%CI 1.00-2.60)。
- 上述关联仅见于有AKI功能学标准的患者;无AKI功能学标准者,生物标志物阳性与阴性30天生存无差异(RR 1.16;95%CI 0.45-3.01)。
证据类型、等级与局限
- 证据类型:基于ProCESS试验数据的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,评估细胞周期停滞标志物TIMP-2与IGFBP7可能增强已有功能学AKI标准患者的分期。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The 23rd Acute Disease Quality Initiative (ADQI-23) consensus conference proposed a framework to integrate biomarkers into the staging of acute kidney injury (AKI). It is unknown whether tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulinlike growth factor binding protein 7 (IGFBP7) could be used for staging.
OBJECTIVE: To test whether higher levels of urinary [TIMP-2] × [IGFBP7] are associated with lower survival among patients with the same functional stage of AKI.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was performed using data from the Protocolized Care for Early Septic Shock (ProCESS) trial, which enrolled critically ill patients with septic shock who presented at academic and community emergency departments and intensive care units in the US from March 2008 to May 2013. Patients with end-stage kidney disease, a reference serum creatinine level of 4 mg/dL or greater (to convert to μmol/L, multiply by 76.25), or missing data on serum creatinine levels or urinary levels of [TIMP-2] × [IGFBP7] were excluded. Data were analyzed from October 2020 to October 2021.
EXPOSURES: The presence of AKI, assessed using Kidney Disease: Improving Global Outcomes criteria within 24 hours after enrollment and the highest AKI stage as well as urinary [TIMP-2] × [IGFBP7] level at 6 hours after enrollment. A previously reported high-specificity cutoff level for [TIMP-2] × [IGFBP7] of 2.0 (ng/mL)2/1000 was used to categorize patients (including those without functional criteria of AKI) according to the new staging system proposed by the ADQI-23 as biomarker negative (urinary [TIMP-2] × [IGFBP7] level ≤2.0 [ng/mL]2/1000) or biomarker positive ([TIMP-2] × [IGFBP7] >2.0 [ng/mL]2/1000).
MAIN OUTCOMES AND MEASURES: Survival (assessed using Kaplan-Meier plots and the log-rank test) and mortality (assessed using relative risk [RR] 30 days after enrollment).
RESULTS: The analysis included 999 patients with a median age of 61 years (IQR, 50-73 years); 554 (55.5%) were male. Biomarker-positive patients had lower survival and higher mortality at 30 days in the groups with AKI stage 1 (RR, 2.20; 95% CI, 1.02-4.72), stage 2 (RR, 1.53; 95% CI, 1.04-2.27), and stage 3 (RR, 1.61; 95% CI, 1.00-2.60). The associations were specific to patients with AKI. No difference in 30-day survival was found between biomarker-positive and biomarker-negative patients in the absence of functional criteria for AKI (RR, 1.16; 95% CI, 0.45-3.01).
CONCLUSIONS AND RELEVANCE: The findings suggest that assessment of the cell-cycle arrest biomarkers TIMP-2 and IGFBP7 may augment AKI staging for patients with functional criteria for AKI.
参考来源
- Molinari L, Del Rio-Pertuz G, Smith A, et al. Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging. JAMA Netw Open. 2022. PMID: 35583867. doi:10.1001/jamanetworkopen.2022.12709
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。